We are excited to announce that CanVirex has moved forward in the development of its lead candidate Mevacil for the treatment of cancer. CanVirex is in preparation of a phase I/IIa trial to assess safety and tolerability of Mevacil in patients with advanced-stage solid cancers. Mevacil is a proprietary, oncolytic measles virus that encodes the genetic information for the cytokine interleukin 12 (IL-12) on its viral genome. Thus,
CanVirex in Pharma Tech Outlook – Cancer vaccination to activate anti-tumor immune response
By Stacey Smith for Pharma Tech Outlook “Cancer is a journey, but you walk the road alone. There are many places to stop along the way and get nourishment—you have to be willing to take it.” (Emily Hollenberg) These lines by Emily Hollenberg, a cancer survivor, give some semblance to the predicament of cancer patients. The torment of cancer continues to grow at an incredible pace, exerting tremendous physical, emotional,
Two sides of the same coin: Measles-vectored drugs for cancer immunotherapy and vaccines
The CanVirex platform deploys the oncolytic properties of recombinant measles vectors for innovative cancer treatments. In addition it has now provided a novel COVID-19 vaccine candidate that is approaching clinical trials. Produced by CanVirex in cooperation with: CanVirex was founded in 2017, based on the research of medical oncologist Guy Ungerechts from the Heidelberg University Hospital and the German Cancer Research Center who is a pio- neer in
Behind CanVirex: From idea to realization
CanVirex stands for ‘fighting cancer with viruses’. Using viruses to treat cancer is an ancient idea, however only in recent decades technologies have been developed to investigate and modify these ’cancer-killing’, or ‘oncolytic’ viruses.